Sri has a passion for emerging, high-growth life science technology companies. Prior to joining the Inscripta team, he was President of Penumbra, an innovative medical devices company, which he led through their IPO. During Sri’s tenure, Penumbra experienced rapid growth with revenues increasing from $125 million to $547 million.
Earlier, Sri spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets.
In addition to his leadership role at Inscripta, Sri is currently a board member for Testing For America and 10x Genomics.
He holds a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.